Denosumab superior to zoledronic acid in delaying first skeletal-related side effect in breast cancer patients
A newly approved drug, denosumab (Xgeva, Amgen), delays skeletal-related side effects for 5 months longer compared to zoledronic acid (Zometa and Reclast, Novartis) in patients with breast cancer and bone metastases, according to phase 3 trial results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.The research, headed by Alison T. Stopeck, MD, associate professor of medicine and director of the Clinical Breast Cancer Program at the University of Arizona’s Arizona Cancer Center, randomized 2,046 patients with advanced breast cancer to receive either 120 mg of subcutaneous denosumab or 4 mg of intravenous zoledronic acid every 4 weeks. Results showed that denosumab was better at delaying the time to first on-study, skeletal-related event by 18% and the time to first and subsequent event by 22%. The median time to first on-study, skeletal-related event was 5 months longer for the denosumab group compared to the zoledronic acid group. Denosumab is more efficacious and better tolerated by patients, Dr. Stopeck said. “Denosumab gives me a new option that is much more convenient, where the patient can have a more normal life, have more normal daily functioning, and spend less time at the cancer center,” she said. “Living with metastatic breast cancer is about quality of life. The less time patients spend with me and the more time they spend with their families and friends is better for everybody. This drug will allow that.” Overall survival and disease progression was similar for both groups. Rates of side effects were 96.2% for those taking denosumab and 97.4% for those taking zoledronic acid. Osteonecrosis of the jaw occurred in 2.5% of patients taking denosumab and 1.8% of those taking zoledronic acid.
FDA approved denosumab starting Nov. 18, 2010, for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
MORE ARTICLES IN THIS ISSUE
"Few patients who are prescribed varenicline to assist in smoking cessation remain on the therapy, according to retrospective data presented during the 45th midyear meeting of the American Society of Health Systems Pharmacists."
Treatment of recurrent herpes simplex labialis with combination 5% acyclovir and 1% hydrocortisone cream is safe in adolescents. In a study of a 5-day treatment course, no safety concerns were identified, said Anders Strand, MD, PhD, at the 45th midyear meeting of the American Society of Health Systems Pharmacists.
FDA is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.
A medication for skeleton-related events in patients with bone metastases was shown to significantly improve bone metastasis-free survival rates in prostate cancer patients, according to a new trial.
A combination of lapatinib, trastuzumab, and paclitaxel significantly improved tumor response rates in patients with HER2-positive breast cancers, according to a new study presented at the San Antonio Breast Cancer Symposium held recently in San Antonio, Texas.